A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Launched by ASTRAZENECA · Apr 19, 2010
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
- • Have completed lung cancer operation
- • The tumour EGFR gene mutation status test was performed as regular medical practice
- Exclusion Criteria:
- • Patients who disagree to participate this study
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Wuhan, Hubei, China
Nanjing, Jiangsu, China
Shenyang, Liaoning, China
Chengdu, Sichuan, China
Suzhou, Jiangsu, China
Beijing, Beijing, China
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Qingdao, Shandong, China
Changchun, Jilin, China
Chongqing, Chongqing, China
Tianjin, Tianjin, China
Patients applied
Trial Officials
Karen Atkin
Study Director
Astrazeneca China R&D
Wu Yilong
Principal Investigator
Guangdong Provincial People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials